1 ur studies demonstrated that doxorubicin and aclarubicin also significantly augmented rAAV transducti

2 r topoII catalytic inhibitors (merbarone and aclarubicin), as well as collaterally sensitive to the D

3                   The anthracycline variants Aclarubicin, Doxorubicinone, and the newly developed Dim

4                                 We show that aclarubicin effectively induces incorporation of exon 7

5 thracycline anticancer drugs doxorubicin and aclarubicin have been used in the clinic for several dec

6  these drugs, we synthesized ten doxorubicin/aclarubicin hybrids varying in three distinct features:

7 ect effect of widely used anticancer agents (aclarubicin, ICRF-193, VM26, doxorubicin, camptothecin,

8            Here, we report that the compound aclarubicin increases the retention of exon 7 into the S

9 suggests that the cancer-killing activity of aclarubicin is driven by the disruption of nucleosomes a

10                             Aclacinomycin A (aclarubicin) is an anthracycline anticancer agent with d

11 that pretreatment of cells with merbarone or aclarubicin, known catalytic inhibitors of topo II, woul

12 served that treatment with the anthracycline aclarubicin leads to elevated levels of RNA polymerase I

13 icin, but not to other catalytic inhibitors, aclarubicin or SN-22995.

14     In addition, another anthracycline drug, aclarubicin, shows similar effects on enhancing nucleoso

15                           In the presence of aclarubicin, the differential sensitivity of BRCA-profic

16                           We also found that aclarubicin treatment changes the distribution of noncan

17  orientation affect chromatin changes during aclarubicin treatment, as closely spaced divergent promo

18  (composed of the idarubicin aglycon and the aclarubicin trisaccharide) stand out, due to their histo

19 he anthracycline derivatives doxorubicin and aclarubicin were chosen for analysis because they have b

20 dent sensitivity was confirmed by the use of aclarubicin, which is a catalytic inhibitor of topoisome

21 ger with duplex DNA, which is different from aclarubicin, which only inhibits Tdp1 with the double-st